Acadian Asset Management LLC boosted its position in Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 36,172.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 17,411 shares of the specialty pharmaceutical company’s stock after purchasing an additional 17,363 shares during the period. Acadian Asset Management LLC’s holdings in Jazz Pharmaceuticals were worth $2,343,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Janus Henderson Group PLC grew its position in shares of Jazz Pharmaceuticals by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after acquiring an additional 866,691 shares during the period. Schroder Investment Management Group purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $52,571,000. Westfield Capital Management Co. LP lifted its stake in shares of Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,438,481 shares of the specialty pharmaceutical company’s stock valued at $210,378,000 after buying an additional 115,217 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,486,426 shares of the specialty pharmaceutical company’s stock valued at $217,390,000 after buying an additional 105,838 shares in the last quarter. Finally, Orbimed Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 16.0% during the 3rd quarter. Orbimed Advisors LLC now owns 749,200 shares of the specialty pharmaceutical company’s stock valued at $109,571,000 after buying an additional 103,300 shares in the last quarter. 93.05% of the stock is owned by institutional investors and hedge funds.
Shares of Jazz Pharmaceuticals plc – (NASDAQ JAZZ) opened at $139.92 on Tuesday. Jazz Pharmaceuticals plc – has a 12-month low of $128.52 and a 12-month high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. The company has a market cap of $8,390.00, a PE ratio of 23.05, a PEG ratio of 0.74 and a beta of 0.99.
A number of analysts recently commented on JAZZ shares. FBR & Co began coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 price target on the stock. Piper Jaffray Companies set a $177.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Saturday, October 21st. Cowen set a $190.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, October 23rd. Stifel Nicolaus restated a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, October 26th. Finally, Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and seventeen have assigned a buy rating to the company. Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $178.51.
In related news, SVP Iain Mcgill sold 8,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the transaction, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at approximately $3,786,859.86. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Matthew P. Young sold 700 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $152.16, for a total transaction of $106,512.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,452 shares of company stock valued at $2,985,885. 4.30% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) Shares Bought by Acadian Asset Management LLC” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/acadian-asset-management-llc-has-2-34-million-position-in-jazz-pharmaceuticals-plc-jazz.html.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.